 |
|
Study shows new method of growth hormone dosing improves height
June 07, 2005New dosing shows 50 percent better growth than traditional approaches
A randomized UCLA study found that a new dosing paradigm can improve height outcomes in the treatment of children who have short stature due to growth hormone deficiency and idiopathic short stature.
The groundbreaking study, presented at The Endocrine Society 2005 meeting in San Diego, Calif., challenges traditional approaches to growth hormone (GH) administration based upon weight.
The authors described a new dosing approach based on the serum levels of insulin-like growth factor-I (IGF-I), the growth hormone GH-dependent hormone that mediates the actions of growth hormone on the growth of children.
In the study, Dr. Pinchas Cohen, lead investigator and professor and chief of pediatric endocrinology at UCLA's Mattel Children's Hospital, along with his UCLA colleagues and collaborators from four institutions, randomized pre-pubertal children with growth hormone deficiency or short stature to one of three treatment arms: a conventional dose of growth hormone according to weight, or to one of two dosing arms where the dose was adjusted to achieve an IGF-I level that was either at the mean for age and gender, or at the upper limit of normal.
Study results showed that the change in height in children whose growth hormone dosage was increased to achieve a higher IGF-I level grew 50 percent better than children receiving fixed doses of growth hormone or whose IGF was maintained at the mean. Furthermore, the higher IGF-I arm resulted in a substantial improvement in the growth of both growth-hormone deficiency patients and patients with idiopathic short stature.
"We feel confident that IGF-based growth hormone dosing could become a novel paradigm in treating growth hormone deficiency, resulting in improved height increases for these children. The growth hormone dose targeted to achieve the higher IGF-I level produced especially meaningful increases in height compared to conventional weight-based methods of determining doses," Cohen said. "Also, the dramatic range of sensitivity to growth hormone in the study population substantiated the rationale for IGF-based dosing. This approach has important implications for both the safety and efficacy of GH."
University of California-Los Angeles
The authors described a new dosing approach based on the serum levels of insulin-like growth factor-I (IGF-I), the growth hormone GH-dependent hormone that mediates the actions of growth hormone on the growth of children.
In the study, Dr. Pinchas Cohen, lead investigator and professor and chief of pediatric endocrinology at UCLA's Mattel Children's Hospital, along with his UCLA colleagues and collaborators from four institutions, randomized pre-pubertal children with growth hormone deficiency or short stature to one of three treatment arms: a conventional dose of growth hormone according to weight, or to one of two dosing arms where the dose was adjusted to achieve an IGF-I level that was either at the mean for age and gender, or at the upper limit of normal.
Study results showed that the change in height in children whose growth hormone dosage was increased to achieve a higher IGF-I level grew 50 percent better than children receiving fixed doses of growth hormone or whose IGF was maintained at the mean. Furthermore, the higher IGF-I arm resulted in a substantial improvement in the growth of both growth-hormone deficiency patients and patients with idiopathic short stature.
"We feel confident that IGF-based growth hormone dosing could become a novel paradigm in treating growth hormone deficiency, resulting in improved height increases for these children. The growth hormone dose targeted to achieve the higher IGF-I level produced especially meaningful increases in height compared to conventional weight-based methods of determining doses," Cohen said. "Also, the dramatic range of sensitivity to growth hormone in the study population substantiated the rationale for IGF-based dosing. This approach has important implications for both the safety and efficacy of GH."
University of California-Los Angeles
Growth Hormone Deficiency Current Events and Growth Hormone Deficiency News RSSGrowth hormone reduces abdominal fat, cardiovascular risk in HIV patients on antiviral therapy
Low-dose growth hormone treatment reduced abdominal fat deposits and improved blood pressure and triglyceride levels in a group of patients with HIV lipodystrophy, a condition involving the redistribution of fat and other metabolic changes in patients receiving combination drug therapy for HIV infection.
Growth hormone treatment for HIV patients improves abdominal fat, but worsens glucose level
For human immunodeficiency virus (HIV)-infected patients with treatment-related abdominal obesity and growth hormone deficiency, receiving low-dose growth hormone resulted in improvement in fat and blood pressure measurements but worsened glucose levels.
Scientists find potential protein biomarkers for growth hormone
Ohio University scientists have identified several proteins in mice that might act as biomarkers for growth hormone. The research could be the first step to finding a more reliable way to detect recombinant human growth hormone (rhGH), which some athletes and teenagers use illegally to boost muscle and reduce fat.
Growth hormone is used to treat twice as many short boys than girls in the US and Asia
Boys are twice as likely as girls in the U.S. and Asia (mostly Japan) to receive recombinant human growth hormone (rhGH) for growth hormone deficiency, illnesses that affect height, and short stature of a non-medical nature.
RNA interference therapy heals growth deficiency disorder in a live animal
A team of Vanderbilt researchers have demonstrated for the first time that a new type of gene therapy, called RNA interference, can heal a genetic disorder in a live animal.
Height affects how people perceive their quality of life
Your height in adult life significantly affects your quality of life, with short people reporting worse physical and mental health than people of normal height.
Growth hormone is not the anti-aging bullet for healthy adults
A review of published data on use of human growth hormone (GH) by healthy elderly people found that the synthetic hormone was associated with small changes in body composition but not in body weight or other clinically important outcomes.
UK Study Suggests Possible Link Between Colorectal Cancer And Human Growth Hormone Therapy (p 273)
Authors of an observational study in this week's issue of THE LANCET highlight a possible link between human growth hormone therapy and an increased risk of colorectal cancer. The investigators comment that further evidence is required before firm conclusions can be made, and stress that there is no evidence from their study as to whether there is an association between modern synthetic growth hormone treatment and increased cancer risk. Human pituitary growth hormone was widely used to counteract short stature in children and young adults up to the mid 1980s; since then synthetic growth hormone has replaced human growth hormone therapy. Previous research has suggested a possible link betwee
Fears raised over link between human growth hormone and CJD
Further cases of Creutzfeldt-Jakob (CJD) disease could arise as a result of human growth hormone treatment, even after low doses, suggests research in the Journal of Neurology Neurosurgery and Psychiatry.
More Growth Hormone Deficiency Current Events and Growth Hormone Deficiency News Articles
 | Growth Hormone Deficiency Medical Guide by Qontro Medical Guides The Growth Hormone Deficiency Medical Guide is a publication which has been designed to better help readers understand Growth Hormone Deficiency. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Growth Hormone Deficiency. The Growth Hormone Deficiency Medical Guide is highly recommended... |
 | Growth Hormone Deficiency - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References by ICON Health Publications In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and... |
| Understanding the Genetics of Growth Hormone Deficiency: A Reference Guide (Lilly Genesis Next Step for Growth) by Roland Pfaffle, Werner F. Blum | |
| Growth Hormone Deficiency in Childhood: Evaluation of Diagnostic Procedures (Monographs in Paediatrics) | |
| Business Wire : Savient and Teva Launch TEV-TROPIN for Pediatric Growth Hormone Deficiency. | |
| Business Wire : Teva and Savient Launch TEV-TROPIN for Pediatric Growth Hormone Deficiency. | |
 | Growth Hormone Deficiency in Adults (Frontiers of Hormone Research) It has been known for over 40 years that GH-deficient children benefit from replacement with the hormone. But GH, essential for longitudinal growth, also plays a role after completion of final height. With the introduction of biosynthetic human GH 20 years ago, the use of GH was no longer restricted to severe growth retardation in hypopituitary children. This book will take the reader behind the... |
| Growth hormone deficiency by Patricia A Rieser | |
| Isolated human growth hormone deficiency and related disorders, by Thomas J Merimee | |
| The molecular basis of growth hormone deficiency (Molecular aspects of medicine) by M Wallis |
| © 2008 BrightSurf.com |